GemPharmatech (SHA: 688046) announced its plan to acquire an 80% equity stake in Baimai Bio in an all‑cash transaction valued at RMB 312 million. Under the terms of the agreement, the founder of Baimai Bio has committed that the company will achieve a cumulative net profit excluding non‑recurring gains and losses of no less than RMB 100 million during the performance commitment period from 2026 to 2028.
Deal Structure
| Item | Detail |
|---|---|
| Acquirer | GemPharmatech (SHA: 688046) |
| Target | Baimai Bio (founded 2018) |
| Stake Acquired | 80% equity |
| Transaction Value | RMB 312 million, all cash |
| Performance Commitment | Cumulative net profit excluding non‑recurring gains and losses of ≥ RMB 100 million over 2026–2028 |
| Committing Party | Founder of Baimai Bio |
| Announcement Date | 16 Nov 2026 |
| Closing Conditions | Not disclosed |
Target Profile – Baimai Bio
- Founded: 2018.
- Business Scope: Dedicated to the research and development of biochemical product technologies, as well as medical research and experimental development.
- Earnings Commitment: The founder’s profit undertaking of ≥ RMB 100 million cumulative (excluding non‑recurring items) across the three years 2026–2028 provides an earnings floor tied to the acquisition.
- Remaining Stake: The disposition of the residual 20% equity interest was not disclosed.
Valuation & Commitment Analysis
- Implied Valuation: The RMB 312 million consideration for 80% implies a 100% equity valuation of RMB 390 million for Baimai Bio.
- Commitment Coverage: The minimum RMB 100 million cumulative net profit commitment over 2026–2028 corresponds to roughly 26% of the implied full equity value, a common earnout‑style protection structure in Chinese all‑cash acquisitions.
- Cash Consideration: The all‑cash structure avoids equity dilution for GemPharmatech shareholders, with payment terms and schedules not disclosed.
- Risk Allocation: Performance commitment periods tied to founder undertakings shift near‑term earnings risk back to the seller if targets are missed, subject to compensation terms that were not disclosed.
Market Impact & Outlook
- Platform Expansion: The acquisition extends GemPharmatech’s capabilities into biochemical product technologies and medical/experimental R&D services, adding an operating business with committed earnings to its portfolio.
- Inorganic Growth: All‑cash purchases of majority stakes with performance undertakings are a standard consolidation route on China’s A‑share market, allowing acquirers to buy profitable assets with contractual downside protection.
- Integration Focus: Post‑closing execution will center on integrating Baimai Bio’s R&D operations and meeting the 2026–2028 profit commitment; synergy targets and integration plans were not disclosed.
- Next Steps: Shareholder and regulatory approvals, if required, and closing timing were not disclosed at announcement.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the completion of the acquisition, satisfaction of closing conditions, Baimai Bio’s ability to achieve the committed cumulative net profit for 2026–2028, and integration outcomes. Actual results may differ due to risks including transaction approvals, business performance against the profit commitment, compensation enforcement, and market conditions. No payment schedule, compensation terms, or synergy estimates have been disclosed.-Fineline Info & Tech
